Digital Vision Solutions: Retina.AI AI-based service for ophthalmologists

The main articles are:

• Blindness
• Sight
• Artificial Intelligence in Medicine
• Artificial intelligence in radiology

2023: Completion of Platform Tests

Federal Scientific and Clinical Center of FMBA of Russia A clinical trial cloudy of the Retina platform was completed at the base.. AI The domestic service for ophthalmologists on the basis artificial intelligence is aimed at the prevention blindness and low vision in people suffering from diabetes mellitus age-related changes in the retina. The FNCC FMBA of Russia announced this on February 8, 2023.

IT actively are integrated medical in services to improve the quality of treatment and diagnosis of various diseases. For example, on the artificial intelligence basis of software algorithms , analyzes images of affected organs and areas, and skin then recognizes pathologies with high accuracy.

The successful completion of clinical trials was another step towards registering the Retina.AI platform at Roszdravnadzor as a medical device and making it available to patients.

The functionality of the platform involves the analysis of photographs of the fundus and scans of optical coherence tomography (OKTAS). The doctor can connect to the service from anywhere in the world and evaluate the processed data during the diagnosis process, which will allow him to get a second medical opinion.

During clinical trials, it was necessary to check the quality of the analysis performed using software algorithms. Specialists of the FKNC FMBA did this on the example of scans of the OKTAS and photographs of the fundus. 180 patients were involved, 301 images were transferred for analysis. The platform performance was evaluated by 3 parameters - accuracy, sensitivity and specificity - and the values ​ ​ obtained are not inferior to the results of the development of the American companies IDX-DX and EyeNook. So, in relation to the analysis of photographs of the fundus, the accuracy indicator is determined at the level of 95%, sensitivity - 96%, and specificity - 91%. In the analysis of scans, OKTAS of rates were 95.6%, 97% and 88.6%, respectively.

We are pleased that clinical trials of the program of automated segmentation of fundus pathologies have been completed on the basis of a research center, like the FNCC FMBA of Russia. The FNCC confirms its high role in introducing current technologies into clinical practice, "said Dmitry Katalevsky, General Director of Didizhital Vision Solutions LLC, developer of the Retina.AI.

Important qualities of the Retina.AI platform are the high accuracy of medical image analysis, ease of use and the large coverage of ophthalmic diseases. These include diabetic retinopathy, diabetic macular edema, vitreomicular interface abnormalities, and a number of other pathologies. The developers of the company "Digital Vision Solutions" directed their efforts to a very socially significant task. In addition, the development of domestic technological solutions in medicine for February 2023 is more relevant than ever "- said Elena Ponomareva, head. Department of Ophthalmology, ophthalmochurigger, laser surgeon of the FNCC FMBA of Russia.